FOLFOX4

DRUG14 trials

Sponsors

Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical Sciences, University of Wisconsin, Madison, Fudan University, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Eli Lilly and Company

Conditions

Advanced Biliary Tract CarcinomaAdvanced Hepatocellular CarcinomaAdvanced Primary Liver CancerCarcinoma, HepatocellularColorectal CancerCytokine-induced Killer CellsGastric CancerHepatocellular Carcinoma

Phase 1

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

CompletedNCT02069041

Eli Lilly and CompanyCarcinoma, Hepatocellular

Start: 2014-04-30End: 2016-09-30Updated: 2018-11-21

Preoperative Radiotherapy And ASTX660 in Rectum Cancer

RecruitingNCT05912075

Gustave Roussy, Cancer Campus, Grand ParisLocally-advanced Rectal Cancer

Start: 2023-12-19End: 2029-01-31Target: 78Updated: 2024-02-08

Phase 2

Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum

TerminatedNCT00580073

University of Wisconsin, MadisonRectal Cancer

Start: 2007-12-31End: 2009-11-30Updated: 2019-12-13

Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)

CompletedNCT02000050

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSRectal Carcinoma

Start: 2013-10-11End: 2019-03-15Updated: 2025-01-30

HR Combined With FOLFOX4 for HCC With PVTT

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-05-31End: 2018-05-31Target: 51Updated: 2015-05-25

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

WithdrawnNCT02527772

Guangxi Medical UniversityHepatocellular Carcinoma

Start: 2015-09-30End: 2018-09-30Updated: 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

WithdrawnNCT02534337

Guangxi Medical UniversityHepatocellular Carcinoma

Start: 2015-09-30End: 2017-09-30Updated: 2019-06-04

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

CompletedNCT03092895

Jiangsu HengRui Medicine Co., Ltd.Advanced Biliary Tract Carcinoma, Advanced Primary Liver Cancer

Start: 2017-04-24End: 2021-03-31Updated: 2026-01-29

Phase 3

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Jiangsu HengRui Medicine Co., Ltd.Advanced Hepatocellular Carcinoma

Start: 2019-05-31End: 2023-12-31Target: 396Updated: 2022-02-10

Phase 4

Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer

CompletedNCT00869271

Fudan UniversityUnresectable Liver Metastasis of Colorectal Cancer

Start: 2005-01-31End: 2007-12-31Updated: 2009-03-25

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Fudan UniversityColorectal Cancer

Start: 2008-01-31End: 2009-12-31Target: 100Updated: 2009-04-02

Chemotherapy Combined With CIK Treating Colon Cancer

CompletedNCT03084809

China Meitan General HospitalColorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications +1

Start: 2012-05-06End: 2014-09-15Updated: 2017-03-21

Unknown Phase

Multicenter and prospective study of chemotherapy associated myelotoxicity among Chinese gastric cancer population receiving cytotoxic conventional regimens

Active, not recruitingChiCTR-ONC-14005147

Gastrointestinal Oncology Department, Affiliated Cancer Center of Academy of Military Medical SciencesGastric Cancer

Start: 2010-08-23Updated: 2017-04-18

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

RecruitingNCT06893887

Nanjing Tianyinshan HospitalHepatocellular Carcinoma(HCC)

Start: 2025-05-22End: 2028-03-15Target: 300Updated: 2025-07-02

Related Papers

Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial

International Journal of Cancer2021-07-2647 citations

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.

2021-05-0324 citations

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Journal for ImmunoTherapy of Cancer2021-03-0169 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial

Therapeutic Advances in Medical Oncology2020-01-011 citations

A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Journal of Clinical Oncology2019-05-2068 citations